Status
Conditions
Treatments
About
Objective of the study is to evaluate the effect of Taxifolin Aqua therapy on the indicators of respiratory function, the state of the arterial wall, the contractile function of the myocardium, as well as to assess the effect of Taxifolin Aqua therapy on markers of biological age, quality of patients life.
Full description
The study will include 100 patients who had covid pneumonia 3 months ago. If the inclusion / exclusion criteria are met, the patient is asked to sign an informed consent to participate in the study. Consenting patients are randomized to an intervention group or a control group. The control group (n = 50) will receive standard therapy, patients from the intervention group (n = 50) will be prescribed Taxifolin Aqua 30 mg per day in addition to standard therapy. Patients will be randomized to the control and main group using random number spreadsheets, assuming that the control and main groups will be homogeneous in the main demographic and clinical parameters. Patient monitoring will be carried out within 2 months from the date of inclusion. A follow-up visit is scheduled in 2 months. During the study, the patient will be regularly monitored for tolerance and safety of therapy with Taxifolin Aqua.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients of both sexes who had covid pneumonia 3 months ago and signed an informed consent and aged 18+.
Exclusion criteria
Standard contraindications to Taxifolin Aqua use.
Primary purpose
Allocation
Interventional model
Masking
100 participants in 2 patient groups
Loading...
Central trial contact
Olga Tkacheva, MD, PhD; Irina Strazhesko, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal